This rising movement shows positive prices direction over last 50 days. Babcock & Wilcox Enterprises had 8 analyst reports since December 15, 2015 according to SRatingsIntel. On Friday, December 4 the stock rating was initiated by Wells Fargo with "Outperform". The stock has "Hold" rating by SunTrust on Thursday, January 19. The rating was maintained by Oppenheimer with "Outperform" on Monday, October 26. The firm has "Hold" rating given on Tuesday, September 19 by KeyBanc Capital Markets.
The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) is a huge mover today! About 914,573 shares traded.
Balyasny Asset Management LLC bought a new position in Sangamo Therapeutics, Inc. It has a 36-month beta of 3.11, so you might be in for a bumpy ride. It was reported on Oct, 13 by Barchart.com.
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company.
In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. The Firm is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. It now has negative earnings. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. This is based on a 1-5 numeric scale where Rating Scale: 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell. Therefore 44% are positive.
05/16/2017 - Sangamo BioSciences, Inc. had its "neutral" rating reiterated by analysts at Wedbush. The rating was maintained by Wedbush on Wednesday, September 2 with "Buy". The stock has "Buy" rating by Jefferies on Friday, October 23. Shore Capital maintained the stock with "Buy" rating in Tuesday, July 18 report. Janney Capital downgraded the stock to "Neutral" rating in Thursday, August 4 report. On Thursday, September 3 the stock rating was maintained by JP Morgan with "Buy". The firm has "Neutral" rating by Wedbush given on Tuesday, November 1.
02/28/2017 - Sangamo BioSciences, Inc. had its "neutral" rating reiterated by analysts at Piper Jaffray. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Sangamo Therapeutics by 0.6% in the second quarter. Finally, BidaskClub cut Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, July 28th.
Since May 11, 2017, it had 0 insider buys, and 2 insider sales for $34,754 activity. Also, VP Curt A. Herberts III sold 15,000 shares of the firm's stock in a transaction dated Monday, October 2nd.
Analysts See Sangamo Therapeutics, Inc. During the same quarter in the previous year, the business earned ($0.38) earnings per share. Sangamo Therapeutics has a 52-week low of $2.65 and a 52-week high of $17.06. It tells an investor how quickly a company is increasing its revenues. Its up 0.79, from 0.8 in 2017Q1.
Shares of Impinj Inc (PI) have seen the needle move -4.14% or -1.55 in the most recent session. Vanguard Group Inc reported 0% stake. When we divide the last trade volume by the 3-month average volume, we found out a relative volume of 0.55. Ubs Asset Mgmt Americas has invested 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Overall, the share price is up 429.51% so far this year. Northern Tru owns 947,832 shares or 0% of their United States portfolio. Cubist Systematic Strategies Limited Liability Corporation holds 0% or 8,176 shares. Credit Suisse Ag holds 376,688 shares or 0% of its portfolio. Point72 Asset Management L P reported 0.02% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Fmr Llc reported 1.61M shares or 0% of all its holdings. Ameritas Investment Ptnrs holds 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 5,756 shares. (NASDAQ:SGMO)'s stock was 421.31%. The short sellers will then buy the stock back at a much lower price and replace the borrowed shares, pocketing the difference. 39 funds opened positions while 62 raised stakes. Ironwood Management Limited accumulated 35,680 shares. Comerica Bancorporation invested 0.02% in Barnes Group Inc. Pillar Pacific Cap Management Llc holds 0.09% of its portfolio in Barnes Group Inc. (NYSE:B) for 11,300 shares. Wasatch Incorporated owns 0.49% invested in Barnes Group Inc. Its shares have trimmed -5.31% since hitting a peak level of $17.06 on October 05, 2017. (NYSE:B) for 12,743 shares. Dimensional Fund Advisors LP boosted its position in shares of Sangamo Therapeutics by 0.4% in the first quarter. Babcock & Wilcox Enterprises Inc (NYSE:BW) has declined 50.61% since October 13, 2016 and is downtrending. It has outperformed by 13.08% the S&P500.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.